A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
Jean‐Luc Harousseau(Institut de Cancérologie de l'Ouest), Lars Möllgård(Karolinska University Hospital), Alan K. Burnett(Cardiff University), Annick Bessems(Johnson & Johnson (Brazil)), А К Голенков(Moscow Regional Research Institute of Obstetrics and Gynecology), Joseph Brandwein(Goethe University Frankfurt), Youn C. Park(Janssen (United States)), Gernot Beutel(Medizinische Hochschule Hannover), Nuriet K. Khuageva(Botkin Hospital), Peter De Porre(Janssen (Belgium)), María‐Belén Vídriales(Complejo Hospitalario de Salamanca), Xavier Thomas(Hôpital Lyon Sud), Giovanni Martinelli(University of Bologna), Elena Tóthová, Johan Maertens(Unknown), Tadeusz Robak(Medical University of Lodz), Tamás Masszi, Dominique Bordessoule(Centre Hospitalier Universitaire de Limoges), W Wiktor-Jędrzejczak(Medical University of Warsaw), Julia A. Alexeeva(City Clinical Hospital), Gert J. Ossenkoppele(Dutch Cancer Society), Hervé Dombret(University of London Institute in Paris), Angela Howes(Johnson & Johnson (Brazil))
Cited by 146
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k